NLight (LASR) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, LASR's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross."A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day ...

After reaching an important support level, Vistra Corp. (VST) could be a good stock pick from a technical perspective. VST recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involves the 50-day an ...

From a technical perspective, Sonic Automotive, Inc. (SAH) is looking like an interesting pick, as it just reached a key level of support. SAH's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.Considered an important signifier for a bullish breakout, a golden cross is a technical chart pattern that's formed when a stock's short-term moving average breaks above a longer-term moving average; the most common crossover involve ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Sco ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? T ...

Key Takeaways GRWG acquires Viagrow to grow its proprietary brand strategy and expand its customer base. Viagrow adds $3M in revenues, and boosts GRWG's e-commerce and mass retail distribution. The deal is expected to raise GRWG's gross margin in 2025 and support more than 30% margin goals.GrowGeneration Corp. (GRWG) announced that it acquired a domestic supplier of gardening and hydroponic equipment, Viagrow. This deal aligns with GRWG’s strategy of driving growth through higher-margin proprietary brands ...

Core Insights - Merck (MRK) has over six blockbuster drugs, with Keytruda being the primary revenue driver, accounting for approximately 50% of pharmaceutical sales [1][9] - Keytruda's sales are increasing due to its rapid adoption in early-stage non-small cell lung cancer (NSCLC) and continued strong performance in metastatic indications [2] - There are concerns regarding Merck's heavy reliance on Keytruda, especially with the impending loss of exclusivity in 2028, prompting the need for diversification [3] Sales and Growth - Keytruda generated sales of $7.21 billion in Q1 2025, reflecting a 6% year-over-year growth, with an estimated compound annual growth rate (CAGR) of 5.4% over the next three years [7][9] - Merck is exploring innovative strategies to sustain Keytruda's growth, including combinations with LAG3 and CTLA-4 inhibitors, and a partnership with Moderna for a personalized mRNA therapeutic cancer vaccine [5][9] Competitive Landscape - Competitive pressure for Keytruda may increase, particularly with Summit Therapeutics' ivonescimab showing promising results in a phase III study, which could challenge Keytruda's market position [4] Future Strategies - Merck is developing a subcutaneous formulation of Keytruda to potentially extend its patent life, with an FDA decision expected in September [6] - The company is also banking on the recently launched pulmonary arterial hypertension (PAH) drug Winrevair to support revenue after Keytruda's exclusivity ends [7] Valuation and Market Performance - Merck's shares have decreased by 19.6% this year, contrasting with a 0.3% increase in the industry [8] - From a valuation perspective, Merck's price/earnings ratio stands at 8.55, which is lower than the industry average of 15.12 and its own 5-year mean of 12.89 [10]

Key Takeaways CYBR posted Q1 ARR of $1.22B, with $46M in net new ARR driven by rising subscriptions and platform use. Subscription ARR hit $1.03B, now nearly 85% of total ARR, underscoring financial stability and growth. New AI tool Secure AI Agent and major machine identity deals highlight CYBR's evolving security strategy.CyberArk Software (CYBR) reported solid first-quarter fiscal 2025 results with Annual Recurring Revenues (ARR) of $1.22 billion, up from $1.17 billion as reported in the last quarter. ...

With just one subscription to Beyond the Wall Investing , you can save thousands of dollars a year on equity research reports from banks. You'll keep your finger on the pulse and have access to the latest and highest-quality analysis of this type of information.I initiated my coverage on Credo Technology Group Holding Ltd (NASDAQ: CRDO ) with a bullish rating in January 2025 , arguing that the CRDO stock's valuation — despite seemingly high multiples — isn't as expensive as many might haveHe leads the inves ...

CANADA - 2025/02/10: In this photo illustration, the Lam Research Corporation logo is seen displayed ... More on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Lam Research (NASDAQ:LRCX) stock has experienced a notable increase this year, rising by 22% and significantly outperforming the S&P 500’s modest gain of 2%. This remarkable performance can be attributed primarily to the company’s solid quarterly results, fue ...